Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas–FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Volume 32, Issue 46, 21 October 2014, Pages 6039–6048
Cancer immunotherapy using a potent immunodominant CTL epitopeLiwen Songa, b, c, d, Ming-Chieh Yangh, Jayne Knoffd, Zu-Yue Sunc, T.-C. Wud, e, f, g, Chien-Fu Hungd, g, , , DOI: 10.1016/j.vaccine.2014.09.021